17 results about "Neoplasm diagnosis" patented technology

The present application relates to the field of tumor markers, in particular to a fascin acetylation modification which can be used as a tumor diagnosis and prognosis analysis marker, a detection reagent and application thereof. The present application is directed to the fact that acetylation modification at K41 site of fascin significantly inhibits the cancer-promoting activity of fascin protein, and in esophageal cancer tissue, the proportion of fascin with acetylation modification at K41 site is significantly lower than that of wild-type fascin in para-cancerous tissue. Based on the acetylation at K41 site of fascin, a specific antibody for acetylation at K41 site of fascin is developed, so as to conduct clinical application research on acetylation at K41 site of fascin, and establish an esophageal cancer prognosis analysis model and targeted treatment.

The present disclosure discloses a brand-new skeleton 99mTc-FAPI diagnostic probe and use thereof in the preparation of a drug or a reagent for diagnosing tumors, wherein the structural formula of a dimeric compound targeting FAP is shown by following formula. Compared with conventional FAP inhibitor radiopharmaceuticals, technetium-99m-labeled novel skeleton FAP inhibitor dimeric compound has a very high tumor uptake rate, high contrast between tumor and background and good in vivo biodistribution.

The application discloses a cervical cancer circRNA marker and application thereof, and belongs to the technical field of biology. The inventors have found that the expression level of circular RNA hsa_circ_0002828 in the plasma of a cervical cancer patient is significantly lower than that in the plasma of a healthy person, thereby indicating that hsa_circ_0002828 can be used as a diagnostic marker for cervical cancer and for predicting the occurrence of cervical cancer. Meanwhile, after overexpression of hsa_circ_0002828, the proliferation ability and invasion ability of cervical cancer cells can be significantly inhibited, and tumor cell apoptosis can be strongly induced. These results show that hsa_circ_0002828 can be used as a tumor diagnosis marker and a potential target for tumor treatment, and is expected to be applied to the diagnosis and treatment of cervical cancer.

There is described herein a method of prognosing or classifying a subject with a Myeloproliferative Neoplasm (MPN) comprising: (a) determining the expression level of at least 10 genes in a test sample from the subject selected from the group consisting of SPP1, CEACAM6, GJA1, IGSF10, IGFBP2, COL4A5, LYVE1, MTIE, EMP1, XIST, DLK1, TPSAB1, TIMP3, CLC, MS4A1, ENKUR, ALOX12, KNDC1, HLA-DQB1, GAS2, CLEC2L, BEND2, CDH7, and NT5E; and (b) comparing expression of the at least 10 genes in the test sample with reference expression levels of the at least 10 genes from control samples from a reference cohort of patients; wherein a difference or similarity in the expression of the at least 10 genes in the test sample and the reference expression levels is used to prognose or classify the subject with MPN into a low risk group or a high risk group for worse survival.

The present application relates to the field of clinical laboratory medicine technology, in particular to a neuroblastoma and catecholamine-related tumor diagnosis kit and its application. The kit contains key components for detecting high vanillylmandelic acid and vanillylmandelic acid in urine, including isotope internal standard, specific chromatographic column, optimized mobile phase and sample pretreatment material. The detection method using the kit optimizes the collection, preservation and pretreatment process of instant urine samples, and combines the liquid chromatography-tandem mass spectrometry (LC-MS / MS) analysis conditions designed for low concentration and complex matrix samples to realize the rapid and accurate quantification of trace HVA and VMA in urine. It overcomes the shortcomings of traditional 24-hour urine detection method such as large trauma, long cycle and poor accuracy, and provides an efficient and reliable solution for non-invasive, early diagnosis and postoperative efficacy monitoring of neuroblastoma and other catecholamine-related tumors, which has important clinical application value.

This invention discloses a 99mTc-FAPI diagnostic probe having a novel skeleton and its application in the manufacture of a tumor diagnostic drug or reagent, the structural formula of the FAP-targeting dimer compound is shown in the following formula. Compared to conventional FAP inhibitor radiopharmaceuticals, the technetium-99m-labeled FAP inhibitor dimer compound having a novel skeleton exhibits a very high tumor uptake rate, high contrast between tumor and background, and good in vivo biological distribution. [C28] TIFF2026518096000031.tif51170

This invention provides a novel target nucleic acid molecule, P7, for the identification of multiple cancer types and its applications. A group of methylated target nucleic acid segments for the diagnosis of multiple pan-cancer diseases were screened and validated. These segments exhibited significant differences in methylation status within tumor samples, which can be used to identify individuals at high risk for cancer. When these target nucleic acid segments are used in combination for detection, they exhibit unexpected improvements in sensitivity and specificity. The tumor target nucleic acid segments of this invention can serve as novel molecules for auxiliary clinical diagnosis or prognosis of cancer.

The present application relates to a kind of C-MET gene and EGFR gene fluorescence in situ hybridization combined detection probe and its application, belong to biological medicine technical field.The present application provides a kind of probe and probe composition for tumor diagnosis and prognosis evaluation, including the first probe for detecting C-MET gene, and the second probe for detecting EGFR gene, the first probe and the second probe are labeled with the first fluorescein and the second fluorescein that can produce different colors respectively;By the present application, a kind of fluorescence in situ hybridization combined detection method and its kit for simultaneously detecting C-MET gene and EGFR gene gene variation are provided;Wide application range can be used in various tissue and cell samples needing simultaneously detecting C-MET gene and EGFR gene state, multiple results are detected once, meet the goal of clinical test quality improvement and efficiency improvement;It has quite extensive application prospect in the prognosis of various cancers.

This application relates to a method, apparatus, computer device, readable storage medium, and computer program product for processing microscope parameters. The method includes: acquiring input microscope parameters in response to a microscope parameter input operation triggered in a displayed microscope parameter input interface; and displaying a report result display interface in response to a microscope parameter calculation operation triggered in the microscope parameter input interface. The report result display interface includes report results for the number of target fields of view corresponding to multiple different types of tumors. The number of target fields of view is the number of nuclear divisions required to observe each type of tumor within the field of view of a target microscope, based on diagnostic criteria for each type of tumor. The target microscope is the microscope corresponding to the microscope parameters. This method can improve the conversion efficiency between microscope field of view and multiple tumor diagnostic criteria.

This invention discloses an exosome-based tumor diagnostic kit and its applications, relating to the fields of medical laboratory science and molecular diagnostics. The kit includes: exosome isolation components; exosome lysis and nucleic acid extraction components; internal standard and quantitative control components; reverse transcription components; molecular detection components; protein detection components; and interpretation and analysis components. This invention achieves complementary fusion of nucleic acid and protein information by simultaneously detecting exosome nucleic acid markers and exosome-derived protein markers from the same blood sample and employing a pre-defined normalization and weighted interpretation algorithm. This fusion strategy overcomes the problem of decreased sensitivity or specificity caused by biological heterogeneity or sample batch variations of single markers, making the identification of early or minor lesions more robust. Simultaneously, through synergistic interpretation among multiple markers, false positive signals originating from benign diseases or physiological fluctuations can be effectively suppressed, thereby improving the reliability of clinical screening and diagnosis.

This invention relates to the field of biomedicine and discloses a monoclonal antibody capable of quantitatively detecting ARRDC4 in exosomes and its applications. This invention provides a novel monoclonal antibody (A-1) capable of quantitatively detecting ARRDC4 in exosomes. This antibody exhibits high specificity, high affinity, high accuracy, and high reproducibility for ARRDC4. Therefore, this antibody can be used to prepare kits for detecting ARRDC4 in exosomes, filling a technological gap in exosomal ARRDC4 detection, establishing a method for tumor diagnosis and prognostic assessment based on exosomal ARRDC4, and providing a new biomarker for liquid biopsy.

This invention discloses a polypeptide PET probe targeting FDG-negative solid tumors, its preparation method, and its application. It belongs to the fields of tumor diagnosis and nuclear medicine imaging. The polypeptide probe primarily targets the CD44v6 protein, as tumors with low FDG uptake often highly express this important target. Specifically, the bifunctional chelating agent NOA is linked to the optimized targeting polypeptide sequence NRWHEDC, and then radioactive nuclide is used for further processing. 18 F or 68 The Ga labeling and purification steps yielded a radionuclide-labeled peptide probe. This probe preparation method is simple and efficient, suitable for large-scale production. More importantly, it possesses high affinity and specificity, enabling PET to identify FDG-negative solid tumors, facilitating early detection, staging, efficacy evaluation, and recurrence monitoring.

This invention discloses an exosomal small non-coding RNA molecular marker and its application, belonging to the field of tumor liquid biopsy and molecular diagnostics. The exosomal small non-coding RNA molecular marker is tRNA-GlyGCC-5; the nucleotide sequence of tRNA-GlyGCC-5 is shown in SEQ ID NO:1. The sRESE in this invention is a novel small non-coding RNA sequence, which is the first discovery by the inventors and has significant implications for the study of esophageal cancer markers and disease progression mechanisms. The tumor diagnostic kit provided by this invention, including the exosomal small non-coding RNA molecular marker, is a non-invasive, highly sensitive, and highly specific liquid diagnostic monitoring kit suitable for general screening or general diagnosis.

The present invention relates to an indole phthalocyanine compound, a preparation method therefor, and a use thereof in tumor diagnosis imaging. Specifically, the present invention relates to a compound having a structure represented by general formula (I) or a pharmaceutically acceptable salt thereof, and a use thereof as a contrast agent. By using the contrast agent of the present invention, near-infrared real-time imaging having high contrast and a clear and distinguishable imaging result can be implemented.

This invention relates to the fields of antibody engineering and tumor diagnosis and treatment technology, specifically to CLDN6 nanobodies that recognize different epitopes and their related applications. To develop more nanobodies that recognize CLDN6, this invention provides two nanobodies capable of recognizing different epitopes of CLDN6, each recognizing a different antigenic epitope of the CLDN6 protein, wherein the different epitopes are spatially independent or partially overlapping. These nanobodies can be used alone or in combination and are suitable for tumor targeted therapy, immunotherapy, in vivo or in vitro diagnostics, and molecular imaging. Compared with existing technologies, the CLDN6 nanobodies provided by this invention have the advantages of small molecular weight, high stability, and strong specificity. Through a multi-epitope recognition strategy, the risk of antigen escape can be significantly reduced, and the targeting binding ability and application flexibility can be improved, making them of significant application value in the diagnosis and treatment of CLDN6-positive tumors.

The present application relates to a kind of C-MYC and FGFR1 gene fluorescence in situ hybridization combined detection probe and its application, belong to biological medicine technical field.The present application provides a kind of probe and probe composition for tumor diagnosis and prognosis evaluation, including the first probe for detecting C-MYC gene, and the second probe for detecting FGFR1 gene, the first probe and the second probe are labeled with the first fluorescein and the second fluorescein that can produce different colors respectively;By the present application, a kind of fluorescence in situ hybridization combined detection method and its kit for simultaneously detecting C-MYC and FGFR1 gene variation are provided;Wide application range can be used in various tissue and cell samples needing simultaneously detecting C-MYC and FGFR1 gene state, one detection, two results, meet the goal of clinical test quality improvement and efficiency improvement;It has quite extensive application prospect in the prognosis of various cancers.